{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:08:14Z","timestamp":1777637294713,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00417-024-06568-w","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T20:02:29Z","timestamp":1722456149000},"page":"3979-3985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Visual recovery after oral high-dose methylprednisolone in acute inflammatory optic neuropathy"],"prefix":"10.1007","volume":"262","author":[{"given":"Elodie","family":"Boureaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuelle","family":"Le Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-4235","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Mouriaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"6568_CR1","doi-asserted-by":"publisher","unstructured":"(1991) The Clinical Profile of Optic Neuritis: Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 109:1673\u20131678. https:\/\/doi.org\/10.1001\/archopht.1991.01080120057025","DOI":"10.1001\/archopht.1991.01080120057025"},{"key":"6568_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM et al (1992) A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis. N Engl J Med 326:581\u2013588. https:\/\/doi.org\/10.1056\/NEJM199202273260901","journal-title":"N Engl J Med"},{"key":"6568_CR3","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S0161-6420(95)30839-1","volume":"102","author":"RW Beck","year":"1995","unstructured":"Beck RW, Trobe JD (1995) What We Have Learned from the Optic Neuritis Treatment Trial. Ophthalmology 102:1504\u20131508. https:\/\/doi.org\/10.1016\/S0161-6420(95)30839-1","journal-title":"Ophthalmology"},{"key":"6568_CR4","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1212\/wnl.52.7.1479","volume":"52","author":"F Sellebjerg","year":"1999","unstructured":"Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52:1479\u20131484. https:\/\/doi.org\/10.1212\/wnl.52.7.1479","journal-title":"Neurology"},{"key":"6568_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","volume":"75","author":"SA Morrow","year":"2018","unstructured":"Morrow SA, Fraser JA, Day C et al (2018) Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial. JAMA Neurol 75:690\u2013696. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0024","journal-title":"JAMA Neurol"},{"key":"6568_CR6","doi-asserted-by":"publisher","unstructured":"Naumovska M, Sheikh R, Bengtsson B, et al (2018) Visual outcome is similar in optic neuritis patients treated with oral and i.v. high-dose methylprednisolone: a retrospective study on 56 patients. BMC Neurol 18:. https:\/\/doi.org\/10.1186\/s12883-018-1165-6","DOI":"10.1186\/s12883-018-1165-6"},{"key":"6568_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jfo.2016.03.008","volume":"39","author":"A Poujade","year":"2016","unstructured":"Poujade A, Le Page E, Baudet D et al (2016) Am\u00e9lioration rapide de la fonction visuelle apr\u00e8s corticoth\u00e9rapie orale \u00e0 forte dose chez des patients atteints de neuropathie optique inflammatoire. J Fr Ophtalmol 39:691\u2013699. https:\/\/doi.org\/10.1016\/j.jfo.2016.03.008","journal-title":"J Fr Ophtalmol"},{"key":"6568_CR8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0140-6736(15)61137-0","volume":"386","author":"E Le Page","year":"2015","unstructured":"Le Page E, Veillard D, Laplaud DA et al (2015) Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet Lond Engl 386:974\u2013981. https:\/\/doi.org\/10.1016\/S0140-6736(15)61137-0","journal-title":"Lancet Lond Engl"},{"key":"6568_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/08820538.2023.2287100","volume":"39","author":"J Pietris","year":"2024","unstructured":"Pietris J, Lam A, Bacchi S et al (2024) The Efficacy, Adverse Effects and Economic Implications of Oral Versus Intravenous Methylprednisolone for the Treatment of Optic Neuritis: A Systematic Review. Semin Ophthalmol 39:6\u201316. https:\/\/doi.org\/10.1080\/08820538.2023.2287100","journal-title":"Semin Ophthalmol"},{"key":"6568_CR10","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.ophtha.2011.11.032","volume":"119","author":"SD Walter","year":"2012","unstructured":"Walter SD, Ishikawa H, Galetta KM et al (2012) Ganglion Cell Loss in Relation to Visual Disability in Multiple Sclerosis. Ophthalmology 119:1250\u20131257. https:\/\/doi.org\/10.1016\/j.ophtha.2011.11.032","journal-title":"Ophthalmology"},{"key":"6568_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/brain\/awr264","volume":"135","author":"SB Syc","year":"2012","unstructured":"Syc SB, Saidha S, Newsome SD et al (2012) Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain 135:521\u2013533. https:\/\/doi.org\/10.1093\/brain\/awr264","journal-title":"Brain"},{"key":"6568_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/1352458515598020","volume":"22","author":"MJ Kupersmith","year":"2016","unstructured":"Kupersmith MJ, Garvin MK, Wang J-K et al (2016) Retinal ganglion cell layer thinning within one month of presentation for optic neuritis. Mult Scler J 22:641\u2013648. https:\/\/doi.org\/10.1177\/1352458515598020","journal-title":"Mult Scler J"},{"key":"6568_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.20851","volume":"59","author":"F Costello","year":"2006","unstructured":"Costello F, Coupland S, Hodge W et al (2006) Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 59:963\u2013969. https:\/\/doi.org\/10.1002\/ana.20851","journal-title":"Ann Neurol"},{"key":"6568_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ana.22005","volume":"67","author":"LS Talman","year":"2010","unstructured":"Talman LS, Bisker ER, Sackel DJ et al (2010) Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 67:749\u2013760. https:\/\/doi.org\/10.1002\/ana.22005","journal-title":"Ann Neurol"},{"key":"6568_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/brain\/awu335","volume":"138","author":"LJ Balcer","year":"2015","unstructured":"Balcer LJ, Miller DH, Reingold SC, Cohen JA (2015) Vision and vision-related outcome measures in multiple sclerosis. Brain 138:11\u201327. https:\/\/doi.org\/10.1093\/brain\/awu335","journal-title":"Brain"},{"key":"6568_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10633-008-9147-4","volume":"118","author":"A Klistorner","year":"2009","unstructured":"Klistorner A, Arvind H, Nguyen T et al (2009) Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. Doc Ophthalmol Adv Ophthalmol 118:129\u2013137. https:\/\/doi.org\/10.1007\/s10633-008-9147-4","journal-title":"Doc Ophthalmol Adv Ophthalmol"},{"key":"6568_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1017\/s0317167100034053","volume":"25","author":"LS Robson","year":"1998","unstructured":"Robson LS, Bain C, Beck S et al (1998) Cost analysis of methylprednisolone treatment of multiple sclerosis patients. Can J Neurol Sci J Can Sci Neurol 25:222\u2013229. https:\/\/doi.org\/10.1017\/s0317167100034053","journal-title":"Can J Neurol Sci J Can Sci Neurol"},{"key":"6568_CR18","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1212\/WNL.0000000000003113","volume":"87","author":"I Kister","year":"2016","unstructured":"Kister I, Corboy JR (2016) Reducing costs while enhancing quality of care in MS. Neurology 87:1617\u20131622. https:\/\/doi.org\/10.1212\/WNL.0000000000003113","journal-title":"Neurology"},{"key":"6568_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neurol.2021.06.009","volume":"178","author":"M Michel","year":"2022","unstructured":"Michel M, Le Page E, Laplaud DA et al (2022) Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial. Rev Neurol (Paris) 178:241\u2013248. https:\/\/doi.org\/10.1016\/j.neurol.2021.06.009","journal-title":"Rev Neurol (Paris)"},{"key":"6568_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326:581\u2013588. https:\/\/doi.org\/10.1056\/NEJM199202273260901","journal-title":"N Engl J Med"},{"key":"6568_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock D, Keller F, Rasche FM, H\u00e4ussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61\u201398. https:\/\/doi.org\/10.2165\/00003088-200544010-00003","journal-title":"Clin Pharmacokinet"},{"key":"6568_CR22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1212\/01.WNL.0000138572.82125.F5","volume":"63","author":"SA Morrow","year":"2004","unstructured":"Morrow SA, Stoian CA, Dmitrovic J et al (2004) The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63:1079\u20131080","journal-title":"Neurology"},{"key":"6568_CR23","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1212\/WNL.52.7.1479","volume":"52","author":"F Sellebjerg","year":"1999","unstructured":"Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52:1479\u20131484","journal-title":"Neurology"},{"key":"6568_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.51.2.529","volume":"51","author":"F Sellebjerg","year":"1998","unstructured":"Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J (1998) Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51:529\u2013534","journal-title":"Neurology"},{"key":"6568_CR25","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1212\/WNL.0b013e3181c3fd5b","volume":"73","author":"V Martinelli","year":"2009","unstructured":"Martinelli V, Rocca MA, Annovazzi P et al (2009) A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS. Neurology 73:1842\u20131848. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c3fd5b","journal-title":"Neurology"},{"key":"6568_CR26","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0140-6736(96)06453-7","volume":"349","author":"D Barnes","year":"1997","unstructured":"Barnes D, Hughes RA, Morris RW et al (1997) Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet Lond Engl 349:902\u2013906","journal-title":"Lancet Lond Engl"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-024-06568-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-024-06568-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T09:03:12Z","timestamp":1732957392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-024-06568-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6568"],"URL":"https:\/\/doi.org\/10.1007\/s00417-024-06568-w","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"20 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the Rennes university hospital (approval number 20.54).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"As this is a retrospective study started before 2016 in France,\u00a0the agreement of the ethics committee is required-see above but informed consent was not necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Patient consent"}},{"value":"No Conflicts of Interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}}]}}